ANDO DALE G 4
4 · SANGAMO BIOSCIENCES INC · Filed Nov 28, 2012
Insider Transaction Report
Form 4
ANDO DALE G
VP, Therapeutic Dev. & CMO
Transactions
- Sale
Common Stock
2012-11-27$5.60/sh−15,000$84,000→ 55,798 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2012-11-27−15,000→ 50,800 totalExercise: $3.61Exp: 2014-08-01→ 15000 (0 underlying) - Exercise/Conversion
Common Stock
2012-11-27$3.61/sh+15,000$54,150→ 70,798 total - Sale
Common Stock
2012-11-26$5.33/sh−4,736$25,232→ 55,798 total
Footnotes (4)
- [F1]The sales resported in this Form 4 were effected pursauant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012, amended on September 12, 2012.
- [F2]The price reported in Column 4 is a weighted average price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.31 to #53501, inclusive. The Reporting person undertakes to provide to Sangamo Biosciences Inc., any security holder of separate price within the manages set forth in footnotes (2) and (3) to this Form 4.
- [F3]Includes 2,000 shares acquired by Reporting Person on October 31, 2012 under the Issuer's Employee Stock Purchase Plan.
- [F4]All shares underlying this option are vested and immediatedly exercisalbe.